Preclinical Small Molecule Program(s)

About Nephraegis Therapeutics

Nephraegis Therapeutics is an emerging biotech targeting the significant unmet need in kidney diseases through a novel approach to renal repair. The company is advancing a pipeline of small molecules designed to enhance mitochondrial function and cellular energetics in injured kidney cells, moving from acute kidney injury towards chronic kidney disease. Founded by a team with deep expertise in nephrology and drug discovery, the company is privately held and in the preclinical development stage. Its strategy involves leveraging its proprietary research platform to identify and validate new therapeutic targets, positioning it as a potential leader in next-generation renal therapeutics.

Therapeutic Areas